AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17164159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 37
Study 17164159 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 37
Study 16027511 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 66
Study 16027511 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 66
Study 16027511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in male partners of infertile couples
Number of subjects: 121
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in oligozoospermic samples
Number of subjects: 121
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 activity and percentage sperm motility
Number of subjects: 121
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 activity and Sperm Mitochondrial Activity Index (SMAI)
Number of subjects: 121
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in azoospermic samples
Number of subjects: 121
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in vasectomised males
Number of subjects: 121
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in immature germ cells
Number of subjects: 121
Study 14510339 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH-C4 as a germinal epithelial marker
Number of subjects: 121
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 3
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 3
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 3
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical replication costs for MET
Number of subjects: 3
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical replication costs for TSF
Number of subjects: 3
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical replication costs for CBT
Number of subjects: 3
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost savings for MET compared to TSF
Number of subjects: 3
Study 9718102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost savings for MET compared to CBT
Number of subjects: 3
Study 7906428 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid plus sulphasalazine
Number of subjects: 11
Study 7906428 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sulphasalazine
Number of subjects: 11
Study 3533371 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 8
Study 3533371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 8
Study 3533371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline and Salbutamol (combined)
Number of subjects: 8
Study 29385034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 140
Study 29385034 — intervention group
Group type: COMPARATOR
Intervention: Low-carb diet
Number of subjects: 140
Study 26604069 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated time‐lapse embryo assessment combined with morphologic assessment
Number of subjects: 319
Study 26604069 — intervention group
Group type: COMPARATOR
Intervention: Morphologic assessment only (control group)
Number of subjects: 319
Study 26604069 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group patients receiving at least one TL‐high embryo
Number of subjects: 319
Study 26604069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving only TL‐low embryos
Number of subjects: 319
Study 26604069 — intervention group
Group type: EXPERIMENTAL
Intervention: TL‐high embryos
Number of subjects: 319
Study 26604069 — intervention group
Group type: EXPERIMENTAL
Intervention: TL‐low embryos
Number of subjects: 319
Study 26604069 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologically good embryos (TL‐high)
Number of subjects: 319
Study 26604069 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologically good embryos (TL‐low)
Number of subjects: 319
Study 23350961 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention designed to enhance motivations to breastfeed delivered in two 35-min classroom sessions.
Number of subjects: 42
Study 23350961 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 42
Study 23451440 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative quadriceps exercise group
Number of subjects: 60
Study 23451440 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 60
Study 20578855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainers
Number of subjects: 40
Study 20578855 — intervention group
Group type: COMPARATOR
Intervention: Perfector/Hawley retainers
Number of subjects: 40
Study 17870625 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural bupivacaine and morphine
Number of subjects: 107
Study 17870625 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve cryoanalgesia
Number of subjects: 107
Study 18987085 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week, 16-hour training in self-management tools based on Easwaran's program
Number of subjects: 61
Study 18987085 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 61
Study 15356075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal atrial natriuretic peptide (ANP) 1 mg
Number of subjects: 18
Study 15356075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11323729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (maximum of 300 mg per day)
Number of subjects: 128
Study 11323729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 11323729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128
Study 9069306 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CT) plus radiation therapy (RT)
Number of subjects: 182
Study 9069306 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 182
Study 8450399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological dose of recombinant human growth hormone (5.0 mg, every other day)
Number of subjects: 10
Study 8450399 — intervention group
Group type: COMPARATOR
Intervention: Physiological dose of recombinant human growth hormone (2.5 mg, every other day)
Number of subjects: 10
Study 3528672 — intervention group
Group type: EXPERIMENTAL
Intervention: G 115 (100 mg twice a day for 12 weeks)
Number of subjects: 16
Study 3528672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31834937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen containing avobenzone (2‐3%)
Number of subjects: 0
Study 31834937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen containing oxybenzone (0‐6%)
Number of subjects: 0
Study 31834937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen containing octocrylene (2.35‐10%)
Number of subjects: 0
Study 31834937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen containing ecamsule (2%)
Number of subjects: 0
Study 29754029 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ users
Number of subjects: 64
Study 29754029 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 64
Study 25708488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg)
Number of subjects: 0
Study 25708488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27129005 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (60 mg)
Number of subjects: 0
Study 27129005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (30 mg)
Number of subjects: 0
Study 21901480 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day isoflavones (aglycone equivalents)
Number of subjects: 431
Study 21901480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 20184052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative radiochemotherapy (PRE)
Number of subjects: 51
Study 20184052 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiochemotherapy (POST)
Number of subjects: 51
Study 17497593 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA drink containing 2 g of BCAA and 0.5 g of Arg
Number of subjects: 8
Study 17497593 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo drink
Number of subjects: 8
Study 15023882 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin
Number of subjects: 45
Study 15023882 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of pravastatin
Number of subjects: 45
Study 15023882 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (375 mg loading dose, followed by 75 mg/d for at least 3 months)
Number of subjects: 45
Study 11135381 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine
Number of subjects: 0
Study 11135381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 10399517 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine scalp circuit infiltration
Number of subjects: 26
Study 10399517 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 26
Study 7771954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (L) 20 mg/day
Number of subjects: 48
Study 7771954 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (P) 10 mg/day
Number of subjects: 48
Study 3402855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (Marcaine, Sensorcaine) instillation into the wound prior to closure
Number of subjects: 0
Study 28512859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful-reappraisal intervention
Number of subjects: 106
Study 28512859 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal-only intervention
Number of subjects: 106
Study 28512859 — intervention group
Group type: COMPARATOR
Intervention: Active control activity
Number of subjects: 106
Study 27630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of the purpose of the study
Number of subjects: 1179
Study 27630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of the procedures of the study
Number of subjects: 1179
Study 27630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of minimal risks associated with answering sensitive questions online
Number of subjects: 1179
Study 27630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding that psychological treatment was not offered
Number of subjects: 1179
Study 27630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect indication of participation replacing current psychological treatment
Number of subjects: 1179
Study 27630213 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect indication of no associated risks with participation
Number of subjects: 1179
Study 26351776 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 supplementation that raised 25(OH)D levels to ≥32 ng/mL
Number of subjects: 35
Study 26351776 — intervention group
Group type: COMPARATOR
Intervention: Continued low 25(OH)D levels (did not receive vitamin D3 supplementation)
Number of subjects: 35
Study 23512062 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (105 mg total over 6 days)
Number of subjects: 1961
Study 23512062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1961
Study 21369538 — intervention group
Group type: EXPERIMENTAL
Intervention: Active distraction (electronic gaming system)
Number of subjects: 100
Study 21369538 — intervention group
Group type: COMPARATOR
Intervention: Passive distraction (television)
Number of subjects: 100
Study 21369538 — intervention group
Group type: COMPARATOR
Intervention: No distraction
Number of subjects: 100
Study 18350850 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste containing Perlite (White System)
Number of subjects: 0
Study 18350850 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica toothpaste
Number of subjects: 0
Study 18350850 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste A
Number of subjects: 0
Study 18350850 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste B
Number of subjects: 0
Study 18350850 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17206893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol drip (Group B)
Number of subjects: 300
Study 17206893 — intervention group
Group type: COMPARATOR
Intervention: Classical IV antispasmodic perfusion with sham drip (Group A)
Number of subjects: 300
Study 17206893 — intervention group
Group type: COMPARATOR
Intervention: Sham perfusion and drip (Group C)
Number of subjects: 300
Study 17206893 — intervention group
Group type: COMPARATOR
Intervention: Sham perfusion and tramadol drip (Group D)
Number of subjects: 300
Study 11807679 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 6 mg/kg b.i.d. for 2 doses, then 3 mg/kg b.i.d. for 6-27 days, followed by 200 mg b.i.d. orally for up to 24 weeks
Number of subjects: 116
Study 11807679 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole in patients with pulmonary or tracheobronchial IA (n=84)
Number of subjects: 116
Study 11807679 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole in patients with cerebral IA (n=19)
Number of subjects: 116
Study 11807679 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole in patients with hematologic disorders (n=67)
Number of subjects: 116
Study 11807679 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole in allogeneic stem cell transplant recipients (n=23)
Number of subjects: 116
Study 10351588 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work preadmission program including psychosocial evaluation, discharge planning, nursing and physiotherapy evaluations, and follow-up during hospitalization.
Number of subjects: 201
Study 10351588 — intervention group
Group type: COMPARATOR
Intervention: Usual social work intervention after hospitalization (comparison group).
Number of subjects: 201
Study 8749780 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 1572
Study 8749780 — intervention group
Group type: COMPARATOR
Intervention: Low or standard dose chemotherapy
Number of subjects: 1572
Study 8749780 — intervention group
Group type: EXPERIMENTAL
Intervention: S-phase fraction (SPF) analysis
Number of subjects: 1572
Study 8749780 — intervention group
Group type: COMPARATOR
Intervention: Different treatment regimens
Number of subjects: 1572
Study 8749780 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 1572
Study 8749780 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF
Number of subjects: 1572
Study 2293142 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg plus paracetamol 1 g 3 times daily
Number of subjects: 158
Study 2293142 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g 3 times daily
Number of subjects: 158
Study 2293142 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 180 mg plus paracetamol 3 g
Number of subjects: 158
Study 7016473 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon cannulas
Number of subjects: 6
Study 7016473 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluorethylene (PTFE) cannulas
Number of subjects: 6
Study 7016473 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene (PE) cannulas
Number of subjects: 6
Study 31462113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 0
Study 31462113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet (VD)
Number of subjects: 0
Study 30630183 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Lactococcus lactis emulsion applied twice daily for 30 days
Number of subjects: 20
Study 30630183 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Lactococcus lactis emulsion applied once daily for 4 days on reconstructed human epidermis
Number of subjects: 20
Study 28369618 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety norm audio
Number of subjects: 120
Study 28369618 — intervention group
Group type: COMPARATOR
Intervention: Control audio
Number of subjects: 120
Study 26358536 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based therapy for pediatric obesity (PBT)
Number of subjects: 0
Study 26358536 — intervention group
Group type: COMPARATOR
Intervention: Parent and child family-based treatment (FBT)
Number of subjects: 0
Study 24145933 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hypertension group (178 patients)
Number of subjects: 432
Study 24145933 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (150 healthy adults)
Number of subjects: 432
Study 24145933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension group (104 patients with no family history)
Number of subjects: 432
Study 22283900 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 1195
Study 22283900 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative individuals
Number of subjects: 1195
Study 22283900 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count < 50 cells/μl
Number of subjects: 1195
Study 22283900 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) initiation
Number of subjects: 1195
Study 19966363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulip-bud deployment method using Amplatzer Septal Occluder (ASO)
Number of subjects: 27
Study 19966363 — intervention group
Group type: COMPARATOR
Intervention: Conventional method for ASD closure
Number of subjects: 27
Study 17727392 — intervention group
Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 32
Study 17727392 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine
Number of subjects: 32
Study 17727392 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and Yohimbine
Number of subjects: 32
Study 17727392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15210457 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UV-B (NB-UV-B) phototherapy, 3 times a week for either 60 treatments or 6 months
Number of subjects: 0
Study 15210457 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 11489463 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-MDE
Number of subjects: 5
Study 11489463 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-MDE
Number of subjects: 5
Study 9471481 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg each morning for 28 days, azithromycin 500 mg/day for 5 days, metronidazole 3 x 500 mg/day for 5 days
Number of subjects: 50
Study 9471481 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day for 28 days, azithromycin 500 mg/day for 5 days
Number of subjects: 50
Study 9471481 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 50
Study 8016577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg bid)
Number of subjects: 30
Study 2455187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 23
Study 2455187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrochlorothiazide (THI)
Number of subjects: 23
Study 2455187 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Prazosin and Dihydrochlorothiazide
Number of subjects: 23
Study 31146148 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Move It (LMI) intervention
Number of subjects: 34
Study 31146148 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 34
Study 28764474 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-reversal permutation with frame lengths of 4-32 ms
Number of subjects: 0
Study 28764474 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization permutation with frame lengths of 1/8 to 2048 ms
Number of subjects: 0
Study 28764474 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-reversal permutation with frame lengths exceeding about 100 ms
Number of subjects: 0
Study 28764474 — intervention group
Group type: EXPERIMENTAL
Intervention: Short frame lengths containing only a few speech samples
Number of subjects: 0
Study 28764474 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-reversal permutation
Number of subjects: 0
Study 28764474 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization permutation
Number of subjects: 0
Study 24969222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 3533
Study 24969222 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3533
Study 24969222 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES) in DM subset
Number of subjects: 3533
Study 24969222 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 3533
Study 24969222 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine angiographic follow-up
Number of subjects: 3533
Study 23721208 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscopic imaging (MEI)
Number of subjects: 200
Study 23721208 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (using fluoroscopy on demand)
Number of subjects: 200
Study 21742090 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 1516
Study 21742090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516
Study 19774117 — intervention group
Group type: EXPERIMENTAL
Intervention: MA‐ES 625 mg/5 mL with a high-calorie, high-fat meal
Number of subjects: 104
Study 19774117 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOS 800 mg/20 mL
Number of subjects: 104
Study 19774117 — intervention group
Group type: COMPARATOR
Intervention: Fasting MA‐ES
Number of subjects: 104
Study 19774117 — intervention group
Group type: COMPARATOR
Intervention: Fasting MAOS
Number of subjects: 104
Study 19774117 — intervention group
Group type: COMPARATOR
Intervention: Fed MA‐ES and MAOS
Number of subjects: 104